Glycosyl phosphatidy linositol specific phospholipase d proteins and uses thereof
CA 2355468 A1 · Owner: Sylus Pharmaceuticals Ltd · Inventors: Schofield, Julian; Rademacher, Thomas William
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Glycosyl phosphatidy linositol specific phospholipase D (GPI-PLD) proteins and their medical uses are disclosed, in particular in the treatment and diagnosis of diabetes and complications of diabetes such as insulin resistance liver , dysfunction, disorders involving pancreatectomies and conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD such , as septic shock. The present invention further relates to variant GPI-PLD polypeptides modified at the phosphorylation site at amino acids 689-692 of the mature human wild-type protein.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 23, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 23, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 23, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.